New chagas drug candidate passes first safety test in small trial
NCT ID NCT05523596
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the safety of an experimental drug called ICM20 in 13 adults with Chagas disease who had not been treated before. Participants took ICM20 along with the standard drug benznidazole. The main goal was to check for side effects and see how many people stayed on the medication for 60 days. Since this was a small safety study, it does not yet show whether ICM20 works better than existing treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ICM20 (a small molecule drug) and benznidazole (a standard Chagas drug)
What this could lead to
If safe, this could support further studies of ICM20 for treating Chagas disease.
What could go wrong
This is a very early Phase 1 safety trial with only 13 participants, so it cannot prove effectiveness. Side effects or lack of benefit may emerge in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Culmore Clinic
Falls Church, Virginia, 22044, United States
-
Parkway Medical
Glen Burnie, Maryland, 21061, United States